What is the 340B Program? Fresh Perspectives

Access to affordable, high-quality healthcare is a lifeline for millions of Americans, especially those who rely on safety‑net providers that serve every patient, regardless of income, insurance status, or background.

The 340B Drug Pricing Program was created to strengthen these providers and ensure that vulnerable patients can get the medicines and care they need. As policymakers review how the program works in practice and advocates raise questions about access and oversight, understanding the program’s real‑world impact has never been more urgent.

Established by Congress in 1992, the 340B program allows eligible healthcare organizations that serve large numbers of underserved patients to purchase outpatient prescription drugs at significant discounts. These savings are intended to help providers reinvest in patient care and protect access to life-changing therapies for the communities that need them most.

For example, many community health centers bring medical care directly to underserved neighborhoods. They provide primary care, behavioral health, chronic disease management, and preventive services to millions. Lower medication costs through the 340B program can help clinics reinvest in care and expand services that directly benefit the communities they serve.

Yet after more than 30 years, the lack of program guardrails has grown while healthcare costs for patients continue to rapidly for patients. According to the Congressional Budget Office (CBO), the program increased from $6.6 billion in drug spending in 2010 to $43.9 billion in 2021. Gaps in oversight and unclear rules have allowed some participants to generate substantial profits without clear evidence that savings are reaching patients or improving community health.

Emerging research further underscores the need for reform. A recent analysis by AiArthritis highlights how 340B hospitals generate large margins by pairing high reimbursement rates with deeply discounted acquisition costs, while new work from the HEAL Collaborative shows these same hospitals are experiencing rapid asset growth even as they reduce uncompensated care.

A National Consumers League analysis further finds that 340B hospitals are more likely than their non-340B counterparts to pursue aggressive medical debt collection practices – including lawsuits, wage garnishment, and liens – even among patients facing serious illnesses like cancer.

Taken together, these trends show why the conversation about strengthening the 340B Program is both timely and necessary.

ASAP 340B is committed to advancing reforms that keep the program patient-focused and community‑driven. Protecting and improving 340B is not just a policy debate; it is essential to preserving the healthcare safety net and ensuring that patients across the country can access the medicines and care they need.